全文获取类型
收费全文 | 6210篇 |
免费 | 430篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 15篇 |
儿科学 | 148篇 |
妇产科学 | 155篇 |
基础医学 | 1138篇 |
口腔科学 | 49篇 |
临床医学 | 731篇 |
内科学 | 1304篇 |
皮肤病学 | 153篇 |
神经病学 | 615篇 |
特种医学 | 106篇 |
外科学 | 633篇 |
综合类 | 15篇 |
一般理论 | 2篇 |
预防医学 | 468篇 |
眼科学 | 72篇 |
药学 | 389篇 |
中国医学 | 11篇 |
肿瘤学 | 648篇 |
出版年
2023年 | 39篇 |
2022年 | 57篇 |
2021年 | 126篇 |
2020年 | 91篇 |
2019年 | 111篇 |
2018年 | 139篇 |
2017年 | 101篇 |
2016年 | 130篇 |
2015年 | 171篇 |
2014年 | 217篇 |
2013年 | 294篇 |
2012年 | 498篇 |
2011年 | 516篇 |
2010年 | 277篇 |
2009年 | 265篇 |
2008年 | 438篇 |
2007年 | 439篇 |
2006年 | 450篇 |
2005年 | 456篇 |
2004年 | 408篇 |
2003年 | 434篇 |
2002年 | 414篇 |
2001年 | 53篇 |
2000年 | 24篇 |
1999年 | 48篇 |
1998年 | 85篇 |
1997年 | 64篇 |
1996年 | 38篇 |
1995年 | 56篇 |
1994年 | 41篇 |
1993年 | 27篇 |
1992年 | 17篇 |
1991年 | 20篇 |
1990年 | 16篇 |
1989年 | 14篇 |
1988年 | 8篇 |
1987年 | 8篇 |
1986年 | 7篇 |
1985年 | 5篇 |
1984年 | 8篇 |
1983年 | 4篇 |
1982年 | 5篇 |
1981年 | 5篇 |
1980年 | 6篇 |
1979年 | 5篇 |
1977年 | 2篇 |
1970年 | 2篇 |
1969年 | 2篇 |
1968年 | 2篇 |
1925年 | 2篇 |
排序方式: 共有6652条查询结果,搜索用时 15 毫秒
101.
102.
Guang Yang Francois X. Caroli-Bosc Catherine Laffont Daniel Bianchi Sylvie Dantin J.-Claude Lefebvre Alain Doglio 《Digestive diseases and sciences》1998,43(6):1307-1310
The aim of this work was to specify the timecourse of response to interferon (IFN) of hepatitis Gvirus (HGV) and hepatitis C virus (HCV) in coinfectedindividuals. A group of 33 patients, undergoing 12 months of IFN therapy for chronic hepatitis C,was screened for the presence of both HGV and HCV RNAsto select seven coinfected patients. Spontaneousrecovery from HGV infection was excluded through the detection of antibodies to the envelope-2protein of HGV and HCV isolates were genotyped. Withinthree months of treatment, we found that HGV RNA wastransiently cleared in 6/7 patients, but the rate of long-term favorable response was very low(1/7). In addition, considering the same individualsseparately, it was shown that HGV and HCV responded toIFN with different kinetics in 5/7 patients. Takentogether, these results underscore the importance of thevirological basis of the resistance to IFNtreatment. 相似文献
103.
Mutations of the Imprinted CDKN1C Gene as a Cause of the Overgrowth Beckwith–Wiedemann Syndrome: Clinical Spectrum and Functional Characterization 下载免费PDF全文
Frederic Brioude Irène Netchine Francoise Praz Marilyne Le Jule Claire Calmel Didier Lacombe Patrick Edery Martin Catala Sylvie Odent Bertrand Isidor Stanislas Lyonnet Sabine Sigaudy Bruno Leheup Séverine Audebert‐Bellanger Lydie Burglen Fabienne Giuliano Jean‐Luc Alessandri Valérie Cormier‐Daire Fanny Laffargue Sophie Blesson Isabelle Coupier James Lespinasse Patricia Blanchet Odile Boute Clarisse Baumann Michel Polak Berenice Doray Alain Verloes Géraldine Viot Yves Le Bouc Sylvie Rossignol 《Human mutation》2015,36(9):894-902
Beckwith–Wiedemann syndrome (BWS) is an imprinting disorder associating macroglossia, abdominal wall defects, visceromegaly, and a high risk of childhood tumor. Molecular anomalies are mostly epigenetic; however, mutations of CDKN1C are implicated in 8% of cases, including both sporadic and familial forms. We aimed to describe the phenotype of BWS patients with CDKN1C mutations and develop a functional test for CDKN1C mutations. For each propositus, we sequenced the three exons and intron–exon boundaries of CDKN1C in patients presenting a BWS phenotype, including abdominal wall defects, without 11p15 methylation defects. We developed a functional test based on flow cytometry. We identified 37 mutations in 38 pedigrees (50 patients and seven fetuses). Analysis of parental samples when available showed that all mutations tested but one was inherited from the mother. The four missense mutations led to a less severe phenotype (lower frequency of exomphalos) than the other 33 mutations. The following four tumors occurred: one neuroblastoma, one ganglioneuroblastoma, one melanoma, and one acute lymphoid leukemia. Cases of BWS caused by CDKN1C mutations are not rare. CDKN1C sequencing should be performed for BWS patients presenting with abdominal wall defects or cleft palate without 11p15 methylation defects or body asymmetry, or in familial cases of BWS. 相似文献
104.
Jean Bousquet Toni Dedeu Eve Dupas Jean-Louis Pépin Landry Stephane Zeng Eyindanga Sylvie Arnavielhe Julia Ayache Xavier Basagana Samuel Benveniste Nuria Calves Venturos Hing Kin Chan Mehdi Cheraitia Yves Dauvilliers Judith Garcia-Aymerich Ingrid Jullian-Desayes Chitra Dinesh Daniel Laune Jade Lu Dac Ismael Nujurally Giovanni Pau Robert Picard Xavier Rodo Renaud Tamisier Michael Bewick Nils E. Billo Wienczyslawa Czarlewski Joao Fonseca Ludger Klimek Oliver Pfaar Jean-Marc Bourez 《Clinical and translational allergy》2018,8(1):36
Allergic rhinitis (AR) is impacted by allergens and air pollution but interactions between air pollution, sleep and allergic diseases are insufficiently understood. POLLAR (Impact of air POLLution on sleep, Asthma and Rhinitis) is a project of the European Institute of Innovation and Technology (EIT Health). It will use a freely-existing application for AR monitoring that has been tested in 23 countries (the Allergy Diary, iOS and Android, 17,000 users, TLR8). The Allergy Diary will be combined with a new tool allowing queries on allergen, pollen (TLR2), sleep quality and disorders (TRL2) as well as existing longitudinal and geolocalized pollution data. Machine learning will be used to assess the relationship between air pollution, sleep and AR comparing polluted and non-polluted areas in 6 EU countries. Data generated in 2018 will be confirmed in 2019 and extended by the individual prospective assessment of pollution (portable sensor, TLR7) in AR. Sleep apnea patients will be used as a demonstrator of sleep disorder that can be modulated in terms of symptoms and severity by air pollution and AR. The geographic information system GIS will map the results. Consequences on quality of life (EQ-5D), asthma, school, work and sleep will be monitored and disseminated towards the population. The impacts of POLLAR will be (1) to propose novel care pathways integrating pollution, sleep and patients’ literacy, (2) to study sleep consequences of pollution and its impact on frequent chronic diseases, (3) to improve work productivity, (4) to propose the basis for a sentinel network at the EU level for pollution and allergy, (5) to assess the societal implications of the interaction. MASK paper N°32. 相似文献
105.
106.
107.
Helene Chapy Sylvie Klieber Priscilla Brun Sabine Gerbal‐Chaloin Xavier Boulenc Olivier Nicolas 《Biopharmaceutics & drug disposition》2015,36(8):491-506
Physiological based pharmacokinetic (PBPK) modeling is now commonly used in drug development to integrate human or animal physiological data in order to predict pharmacokinetic profiles. The aim of this work was to construct and refine a PBPK model of irbesartan taking into account its active uptake via OATP1B1/B3 in order to predict more accurately its pharmacokinetic profile using Simcyp®. The activity and expression of the human hepatocyte transporters OATP1B1 and OATP1B3 were studied. The relative activity factors (RAFs) for OATP1B1 and OATP1B3 transporters were calculated from intrinsic clearances obtained by concentration dependent uptake experiments in human hepatocytes and HEK overexpressing cells: RAF1B1 using estrone‐3‐sulfate and pitavastatine clearances, and RAF1B3 using cholecystokinine octapeptide (CCK‐8) clearances. The relative expression factor (REF) was calculated by comparing immunoblotting of hepatocytes (REFHH) or tissues (REFtissue) with those of overexpressing HEK cells for each transporter. These scaling factors were applied in a PBPK model of irbesartan using the Simcyp® simulator. Pharmacokinetic simulation using REFHH (1.82 for OATP1B1, 8.03 for OATP1B3) as an extrapolation factor was the closest to the human clinical pharmacokinetic profile of irbesartan. These investigations show the importance of integrating the contribution of the active uptake of a drug in the liver to improve PBPK modeling. Copyright © 2015 John Wiley & Sons, Ltd. 相似文献
108.
109.
110.